Last week it was announced a drogant giant to sell European rights to Necium and global rights, other than the US and Japan, at Vim's Grunenthal.
Now sell including the rights of Alvesco, Omnaris and Zetone. The buyer is a Swiss pharmaceutical company Covis Pharma, and the price is $ 350 million. Astrazeneca is then entitled to a fee of $ 21 million for a four-year period from 2019.
Covis Pharma is currently selling three drugs in US markets and now has rights in markets outside the US.
The transaction does not include any transfer of workers or objects to Astrazenec.